While targeting both IL6 and CCR2 appears to be a promising therapeutic approach for HPV − HNSCC, it is critical to recognize that factors beyond NK cell stimulation may contribute to the divergent response to IL6/CCR2 double blockade between HPV − and HPV + tumors. Here, IL6 is linked to head and neck squamous cell carcinoma.